Literature DB >> 26124807

Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G.

Liu Xiaoyang1, Ni Chenming2, Li Chengqing3, Liu Tao4.   

Abstract

BACKGROUND: Gomisin G, isolated from herb Schisandra chinensis, exhibits anti-tumor activities. Therefore, Gomisin G is a drug candidate for anti-liver cancer therapy. AIMS: To predict the metabolic behavior and metabolism-based drug-drug interaction of gomisin G.
METHODS: Molecular docking method was used. The crystal structure of CYP3A4 with the ligand ketoconazole was chosen from protein data bank (http://www.rcsb.org/pdb). Chemdraw software was used to draw the two-dimensional structure of gomisin G with standard bond lengths and angles.
RESULTS: Gomisin G can be well docked into the activity site of CYP3A4, and distance between gomisin G the heme active site was 2.75 Å. To evaluate whether the inhibitors of CYP3A4 can affect the metabolism of gomisin G, co-docking of gomisin G and ketoconazole was further performed. The distance between ketoconazole and activity center (2.10 Å) is closer than the distance between gomisin G and activity center of CYP3A4, indicating the easy influence of CYP3A4's strong inhibitor towards the metabolism of gomisin G.
CONCLUSION: Gomisin G is a good substrate of CYP3A4, and CYP3A4 inhibitors easily affect the metabolism of Gomisin G.

Entities:  

Keywords:  CYP3A4; Gomisin G; molecular docking

Mesh:

Substances:

Year:  2015        PMID: 26124807      PMCID: PMC4480504          DOI: 10.4314/ahs.v15i2.35

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  9 in total

1.  Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole.

Authors:  Tao Liu; Ge Qian; WenTing Wang; YanGuo Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-23       Impact factor: 2.441

2.  Isolation of lignans from Schisandra chinensis with anti-proliferative activity in human colorectal carcinoma: Structure-activity relationships.

Authors:  John Gnabre; Irem Unlu; Tso-Cheng Chang; Paul Lisseck; Bryan Bourne; Ryan Scolnik; Neil E Jacobsen; Robert Bates; Ru Chih Huang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-08-14       Impact factor: 3.205

3.  Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.

Authors:  Zhong-Ze Fang; Yan-Yan Zhang; Guang-Bo Ge; Hong Huo; Si-Cheng Liang; Ling Yang
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 4.  LC-MS-based metabolomics: an update.

Authors:  Zhong-Ze Fang; Frank J Gonzalez
Journal:  Arch Toxicol       Date:  2014-04-08       Impact factor: 5.153

Review 5.  Alcohol and HCV: implications for liver cancer.

Authors:  Gyongyi Szabo; Banishree Saha; Terence N Bukong
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

6.  Metabolic map and bioactivation of the anti-tumour drug noscapine.

Authors:  Zhong-Ze Fang; Kristopher W Krausz; Fei Li; Jie Cheng; Naoki Tanaka; Frank J Gonzalez
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

7.  Antitumor and antiangiogenic activity of Schisandra chinensis polysaccharide in a renal cell carcinoma model.

Authors:  Hai-Ming Qu; Shi-Jian Liu; Chun-Ying Zhang
Journal:  Int J Biol Macromol       Date:  2014-02-18       Impact factor: 6.953

8.  CYP3A catalyses schizandrin biotransformation in human, minipig and rat liver microsomes.

Authors:  Y-F Cao; Y-Y Zhang; J Li; G-B Ge; D Hu; H-X Liu; T Huang; Y-C Wang; Z-Z Fang; D-X Sun; H Huo; J Yin; L Yang
Journal:  Xenobiotica       Date:  2010-01       Impact factor: 1.908

9.  Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation.

Authors:  Kana Kobayashi; Ohgi Takahashi; Masahiro Hiratsuka; Noriyuki Yamaotsu; Shuichi Hirono; Yurie Watanabe; Akifumi Oda
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

  9 in total
  4 in total

1.  Infectious diseases and chronic care in Africa.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

2.  A Molecular Basis for the Inhibition of Transient Receptor Potential Vanilloid Type 1 by Gomisin A.

Authors:  Sung Bae Lee; Shinhwa Noh; Hye Duck Yeom; Heejin Jo; Sanung Eom; Yoon Suh Kim; Sangsoo Nam; Hyunsu Bae; Jun-Ho Lee
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-26       Impact factor: 2.629

3.  Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism.

Authors:  Baiping Dong; Suowei Yuan; Jinsheng Hu; Yanzhen Yan
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

4.  Gomisin G Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing AKT Phosphorylation and Decreasing Cyclin D1.

Authors:  Sony Maharjan; Byoung Kwon Park; Su In Lee; Yoonho Lim; Keunwook Lee; Hyung-Joo Kwon
Journal:  Biomol Ther (Seoul)       Date:  2018-05-01       Impact factor: 4.634

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.